Kinnate Biopharma Inc (DELISTED) (KNTE:DL)
2.65
0.00 (0.00%)
USD |
NASDAQ |
Apr 03, 16:00
Kinnate Biopharma SG&A Expense (Quarterly): 5.734M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.734M |
| September 30, 2023 | 6.605M |
| June 30, 2023 | 7.808M |
| March 31, 2023 | 8.094M |
| December 31, 2022 | 7.496M |
| September 30, 2022 | 7.824M |
| June 30, 2022 | 7.639M |
| March 31, 2022 | 7.412M |
| December 31, 2021 | 6.73M |
| Date | Value |
|---|---|
| September 30, 2021 | 6.073M |
| June 30, 2021 | 5.327M |
| March 31, 2021 | 4.815M |
| December 31, 2020 | 1.743M |
| September 30, 2020 | 2.019M |
| June 30, 2020 | 2.047M |
| March 31, 2020 | 0.955M |
| December 31, 2019 | 0.926M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.926M
Minimum
Dec 2019
8.094M
Maximum
Mar 2023
5.250M
Average
6.073M
Median
Sep 2021
SG&A Expense (Quarterly) Benchmarks
| XOMA Corp | 8.461M |
| Societal CDMO Inc (DELISTED) | 5.781M |
| NGM Biopharmaceuticals Inc (DELISTED) | 7.938M |
| Avrobio Inc | 7.258M |
| Landos Biopharma Inc (DELISTED) | 6.144M |